Scintillator nanocrystal-containing compositions and methods for their use
There are provided, inter alia, compositions including a scintillator nanocrystal linked to a chemical agent moiety through a scintillator-activated photocleavable linker, and methods of use thereof.
1. A composition, comprising:
(i) a scintillator nanocrystal comprising (Y 1-x Pr x ) 3 Al 5 O 12 , where x is 0.01;
(ii) a chemical agent moiety comprising doxorubicin; and
(iii) a scintillator nanocrystal-activated photocleavable linker comprising:
wherein said linker operably links said scintillator nanocrystal and said chemical agent moiety.
2. The composition of claim 1 , wherein said scintillator nanocrystal comprises a host crystal lattice.
3. The composition of claim 1 , wherein said scintillator nanocrystal has a diameter from 25 nm to 300 nm.
4. The composition of claim 1 , wherein said composition downconverts incident energy to emission energy that is less than said incident energy; wherein said incident energy comprises energy that is in the X-ray range, the gamma-ray range, or a combination thereof; and wherein said emission energy comprises energy that is in the UV range.
5. The composition of claim 1 , wherein said scintillator nanocrystal emits photon emission peaks within 300 nm to 470 nm.
6. The composition of claim 1 , wherein said scintillator-activated photocleavable linker cleaves and releases said chemical agent moiety upon absorbing photons from 100 nm to 600 nm.
7. The composition of claim 1 , wherein said scintillator-activated photocleavable linker is covalently attached to said chemical agent moiety and a surface of said scintillator nanocrystal.
8. The composition of claim 7 , wherein said surface is a lipid bilayer surface.
9. The composition of claim 7 , wherein said surface is a silinated surface.
10. The composition of claim 1 , wherein said composition can be used to treat tumors, deep tumors, or a combination thereof.
11. The composition of claim 1 , wherein said composition can be used to treat an infection.
12. The composition of claim 1 , wherein said composition is in a powdered form.
13. The composition of claim 1 , wherein said composition is in solid form or suspended in a liquid.
14. A composition comprising:
(i) a scintillator nanocrystal comprising (Y 1-x Pr x ) 3 Al 5 O 12 , where x is 0.0075, 0.01, 0.0125, 0.015, or 0.0175;
(ii) a chemical agent moiety comprising an anti-cancer drug moiety; and
(iii) a scintillator nanocrystal-activated photocleavable linker comprising:
wherein n3 is an integer from 0 to 5; and L 1 is bond, —C(O)—, —C(O)O—, —O—, —S—, —NH—, —C(O)NH—, —NHC(O)—, —S(O) 2 -, —S(O)NH—, substituted or unsubstituted alkylene, substituted or unsubstituted heteroalkylene, unsubstituted cycloalkylene, substituted or unsubstituted heterocycloalkylene, substituted or unsubstituted arylene, or substituted or unsubstituted heteroarylene;
wherein said linker operably links said scintillator nanocrystal and said chemical agent moiety.
15. The composition of claim 14 , wherein the anti-cancer drug moiety is doxorubicin.
16. The composition of claim 14 , wherein x is 0.01.
17. The composition of claim 14 , wherein the scintillator nanocrystal-activated photocleavable linker comprises:
18. The composition of claim 1 , wherein the scintillator nanocrystal produces two photon emission peaks between 300 nm and 400 nm when exposed to an X-ray of 50 keV.
19. The composition of claim 1 , wherein the scintillator nanocrystal produces a photon emission peak between 350 nm and 400 nm when exposed to an X-ray of 50 keV.
20. The composition of claim 14 , wherein the scintillator nanocrystal produces two photon emission peaks between 300 nm and 400 nm when exposed to an X-ray of 50 keV.
21. The composition of claim 1 , wherein the scintillator nanocrystal produces a photon emission peak between 350 nm and 400 nm when exposed to an X-ray of 50 keV.